AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2021
May 5, 2021
31523_dirs_2021-05-05_dc3c9f16-33fc-44cd-8472-0d2a21333308.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-05-03
Reporting Person: MCGLYNN MARGARET G (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-03 | Common Stock | M | 10000 | $7.51 | Acquired | 37919 | Direct |
| 2021-05-03 | Common Stock | S | 10000 | $10.2704 | Disposed | 27919 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-03 | Stock Options (right to buy) | $7.51 | M | 10000 | Disposed | 2021-05-24 | Common Stock (10000) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.24 to $10.39 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: All of these options were fully vested and exercisable as of the transaction date.